FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC
The US FDA has provided a complete response letter for Daiichi Sankyo and MSD’s BLA for patritumab deruxtecan to treat NSCLC.
The US FDA has provided a complete response letter for Daiichi Sankyo and MSD’s BLA for patritumab deruxtecan to treat NSCLC.
What's Your Reaction?
